My Passport
News and Commentary education Live Coronavirus Dashboard
S&P 500 ETF
0.00%
NASDAQ ETF
0.00%
Dow Jones ETF
0.00%


Nike Q2 Earnings: Revenue Beat, EPS Beat, Sha...
FedEx Stock Rallies On Better-Than-Expected Q...
Disney Hits $2 Billion Domestic Box Office, E...
Amazon Shares Rise As Company Says Operations...
4 Micron Analysts Size Up Q1 Earnings: 'An Op...
Block Positioned For Margin Expansion And EPS...
Birkenstock's High-end Lifestyle Positioning...
Astronauts Sunita Williams, Butch Wilmore's...
The Rise of the Solo General Partner Investor

While modern day venture capital originated in the 1940s, the very first iteration of venture capital (VC) investments--where a general partner (GP) investments capital on behalf of a limited partner (LP)--dates all the way back to the early 1600s with the founding of East India...

  • How are Higher Rates Impacting the Housi...
  • Quantitative Tightening: How the Fed Co...
  • Should Investors Worry About Inflation?
  • How Semiconductors are Made and Why its...
  • What Are NFTs?
    • Inflation: What is it and How to Protect From...
    Short Squeezes Could Lead to Market Dislocati...
    How Google and Facebook Antitrust Lawsuits Co...
    Vaccine News Triggers Growth to Value Rotatio...
    Energy
    Materials
    Industrial
    Finance
    Consumer D...
    Consumer S...
    Informatio...
    Telecommun...
    Health Car...
    Utilities
    Oil
    Gold
    ETFs IPOs Ratings
     
    S&P 500 ETF
    0.00%
    NASDAQ ETF
    0.00%
    Dow Jones ETF
    0.00%
    Search
    News and Commentary
    Education
    Market
    ETFs
    IPOs
    Ratings
    Newsfeed
    My passport
    Login
    Sign up

    SAGE THERAPEUTICS INC (NASDAQ: SAGE)

    Overview
    current price
    $5.61
    $5.61
    change
    0.61 | 12.20%
    0.61 | 12.20%
    Yesterday's Close
    5.00
    open
    5.06
    volume
    4.34 M
    30d. avg volume.
    0.93 M
    1 day
    4.95 - 5.62
    52 weeks
    4.62 - 28.26
    p/e
    0.00
    beta
    0.8693
    market cap
    0.34 B
    dividend yield
    0.00%
    Industry
    -
    SAGE by TradingView
    News and Commentary
    New Drug to Treat Schizophrenia Approved by FDA The U.S. Food and Drug Administration (FDA) has approved Caplyta (lumateperone), a drug developed by Intra-Celullar Therapies Inc.
    Neuro Drug Stocks Rise Following Intra-CellularTherapies' Drug Approval One indisputable trend about the modern world is that people are living longer. In 1950, the average lifespan for an American was 68 years old. Today, it's 78. One result of a lo...
    StockTwits
    StockTwits
    Most Shared
    Nordstrom Q3 Sales Grow, But Analysts Remain Cautious On Stock Amid Slowing Sales And Elevated Inventory
    Warner Bros Discovery Stock Soars After Multi-Year Deal with Comcast; Comcast Shares Slide On Subscriber Loss Estimates
    Apple's iPhone 16 Stumbles On 'Intelligence' Awareness, But Pro Max Shines Bright: Analyst
    Most Popular
    Market Update: Dow, S&P 500 Climb in Best Month of 2024
    Consumer Confidence Hits 2-Year High As Recession Fears Fade: Stock Market Optimism Soars To Record High
    Nordstrom Q3 Sales Grow, But Analysts Remain Cautious On Stock Amid Slowing Sales And Elevated Inventory
    popular tags
    Earnings
    Coronavirus
    Apple
    Amazon
    Coronavirus Impact
    Covid-19
    Google
    Covid19
    Tesla
    mobile iOS
    social Facebook Twitter Youtube Linkedin Rss Google News
    Passport to Wall Street About Us Contact Advertise Privacy Policy Terms of Service
    Sign Up
    © 2024 Passport to Wall Street
    Quotes are at least 20 minutes delayed

    Join now and unlock premium features

    Already Have An Account?